Protocol Ledger

NCT06180356 · Phase II · RECRUITING

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression

Interventional Phase II clinical trial protocol NCT06180356 sponsored by MedSIR in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-03 Enrollment: 30 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06180356
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)30 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06180356
Protocol FieldVerified Registry Value
NCT IdentifierNCT06180356
Consolidated Lead SponsorMedSIR
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment30 participants (ESTIMATED)
Registered Start Date2024-12-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI